Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

ACEI/ARBs fight off confusion among hypertensive COVID-19 patients

21 Nov 2020

The use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) seem to protect against confusion in patients of the novel coronavirus disease (COVID-19) with hypertension, a recent Japan study has found.

The study included 151 COVID-19 patients, of whom 39 were hypertensive (mean age, 71±12 years; 69.2 percent male). The primary outcome was a composite of in-hospital death, extracorporeal membrane oxygenation, invasive and noninvasive mechanical ventilation, and admission into the intensive care unit (ICU). Outcomes were compared to 112 patients without hypertension (mean age, 56±20 years; 56.3 percent male).

Of the 39 hypertensive participants, 22 were on ACEI/ARB medication. Fourteen in-hospital deaths were recorded, yielding an overall rate of 9.3 percent. Fourteen and 58 patients required mechanical ventilation or oxygen therapy, respectively.

Multivariate logistic regression analyses showed that age was the strongest and most consistent risk factor for all outcomes assessed. Participants ≥65 years of age, for example, saw a sixfold spike in the likelihood of the primary composite outcome occurring (odds ratio [OR], 6.63, 95 percent confidence interval [CI], 2.28–22.78; p<0.001).

Similarly, these patients were more than four times as likely to develop the secondary composite endpoint (OR, 4.53, 95 percent CI, 1.72–13.20; p=0.002), which included low admission systolic blood pressure and new-onset or worsening mental confusion, among others.

Notably, while ACEI/ARB use had no significant benefit with regard to the primary and secondary composite outcomes, it exerted a significant protective effect against new-onset confusion, reducing the odds by nearly 90 percent (OR, 0.13, 95 percent CI, 0.01–0.93; p=0.041).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.